Presented results demonstrated that patients in the study's bavituximab treatment arm who had low baseline PD-L1 expression levels had a statistically significant improvement in median overall survival (mOS) as compared to patients in the same treatment arm who had higher baseline levels of PD-L1.
Excellent....thanks CJ and now Peregrine can show some us hopefully some situations where and when dosing with PS Targeting can penetrate a sizable market share, that will prove to be valuable to just about any BP
Pit a few of them against one a other and show them how valuable PS Targeting truly is...
Market Data 
Markets 
AI
